
Opinion|Videos|February 6, 2025
Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies
Panelists explore how the introduction of tyrosine kinase inhibitors (TKIs) could affect the perceived benefits of the port delivery system, as these agents may offer an alternative approach to reducing injection burden while potentially providing broader therapeutic effects.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- If TKIs become available, how would this impact the relative benefits of PDS?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
2
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
3
Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
4
Ophthalmic drug shortages more frequent, longer lasting than average
5



































